Tag Archives: Sandra Horning

Roche’s phase III CAPSTONE-2 study showed superior efficacy of baloxavir marboxil in reducing influenza symptoms in people at high risk of complications from the flu

Posted on 18, July 2018 by

Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in high-risk patients Influenza, or “flu,” represents a serious threat … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , ,

Roche’s Tecentriq in combination with Avastin receives FDA Breakthrough Therapy Designation as initial treatment for advanced or metastatic hepatocellular carcinoma

Posted on 18, July 2018 by

BASEL, 18-Jul-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , , ,

Roche: Phase III IMpower131 study met its co-primary endpoint of progression-free survival of people with a type of advanced squamous lung cancer

Posted on 20, March 2018 by

BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , , , , ,

Roche’s Lucentis is the first and only FDA-approved medicine to treat diabetic retinopathy

Posted on 24, April 2017 by

First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of Health (NIH)-funded collaborative group study BASEL, 24-Apr-2017 — /EuropaWire/ — Roche (SIX: … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , ,

New Data on Roche’s OCREVUS To be Presented at AAN

Posted on 24, April 2017 by

Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis BASEL, 24-Apr-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , ,

Roche’s Perjeta recommended for approval in EU as pre-surgery breast cancer treatment

Posted on 29, June 2015 by

The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the benefit in achieving pathological complete response (pCR) BASEL, 29-6-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , ,

Roche: New data in rheumatoid arthritis and other severe autoimmune conditions will be presented at European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, 10-13 June 2015

Posted on 29, May 2015 by

40 data presentations across 7 autoimmune conditions, including new results from RoACTEMRA in early RA and systemic sclerosis (SSc) – a potentially fatal disease with limited treatment options¹ BASEL, 29-5-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today … Read the full press release →

Posted in Healthcare, Management, Marketing, Pharma & Biotech, Switzerland

Tagged , , , , , ,

Roche subcutaneous formulation of RoACTEMRA received European Commission approval for moderate to severe rheumatoid arthritis treatment

Posted on 29, April 2014 by

First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received approval from … Read the full press release →

Posted in Business, European Union, Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , ,